which can be changed to the activated state by extracellular stimuli such as the presence of mitogens, cytokines and growth factors. 6 On activation, Ras exerts its functions through protein-protein interactions with effectors, such as Raf kinase and PI3K, to promote cell growth and survival. 7, 8 In 1982, mutant Ras genes were detected in human cancers, marking the first discovery of mutated genes in cancer patients. 9 Indeed, Ras mutations are genetic events that have been detected in 30% of all human cancers, with the specific Ras isoform generally differing according to the cancer type. 6 Mutations in K-Ras account for approximately 85% of all Ras mutations, those in N-Ras for approximately 15% and those in H-Ras for less than 1%; these are single base missense mutations, mainly in codons 12, 13 or 61 of exons 2 and 3. 5, 10, 11 In colon and rectal carcinomas, K-Ras is also the predominantly mutated isoform, whereas N-Ras mutations are infrequent, and H-Ras mutations have not been detected. 12 Cancer-causing mutations impair the GTPase activity of Ras, causing Ras to accumulate in the GTP-bound active state, which transmits strong downstream signals. 6 The epidermal growth factor receptor (EGFR) is an important molecule involved in cancer biology and therapy. 13 K-Ras, which is an essential component of the EGFR signaling cascade, can activate downstream growth-related signaling pathways Raf-MAPK and PI3K/AKT. 14 Both increased EGFR expression and elevated gene copy numbers are seen in colorectal cancers. 15 For metastatic colorectal cancer patients that have not responded to chemotherapy, cetuximab, which is an IgG1 chimeric monoclonal antibody against EGFR, improves overall and progression-free survival. 16 Unfortunately, the effectiveness of cetuximab is currently limited to patients with wild-type K-Ras tumors. 16 In patients with mutated K-Ras tumors, there is no significant difference between those who were treated with cetuximab and those who received supportive care alone with respect to overall survival or progression-free survival. 16 So far, extensive efforts have been made to develop one or more small chemical compounds that could directly target and inhibit constitutively active K-Ras. 6, 17 However, direct pharmacological targeting of activated K-Ras has been so unsuccessful for clinical use that Ras oncoproteins are considered to be "undruggable" cancer targets. Therefore, there is a need for the development of new strategies and technologies to attack mutated K-Ras.
Recently, microRNA (miRNA), which is a small nucleic acid molecule, has begun to revolutionize the world of drug discovery. 18, 19 Impairment of the intracellular levels of certain miRNA triggers the transmission of genetic information conductive to the development of disease. 20, 21 We previously reported that tumor suppressor miR-143 is downregulated in approximately 80% of human colorectal tumor samples from cancer and adenoma patients compared with its level in normal tissues. 22 The basic concept of miRNA therapy is restoration of the normal condition by replacing downregulated miRNA in tumor cells. 23, 24 For instance, MRX34, which is an miR-34, was demonstrated to be somewhat effective in clinical trials on liver cancer patients. 25 However, for clinical application, the problem of degradation by RNA nuclease must be solved; and more efficient modification of miRNA and their drug delivery system must be devised. 26 In this present study, we synthesized mature miR-143 (syn-miR-143) targeting K-Ras mRNA, 27 and others such as AKT and ERK mRNA. [28] [29] [30] Among them, a chemically-modified miR-143 (miR-143#12) induced growth inhibition of K-Ras mutant colon cancer cell lines when tested at an extremely low concentration. In addition, miR-143#12 effectively restored the anti-cancer activity of cetuximab (anti-EGFR antibody) against cancer cells by impairing of K-Ras signaling networks. Presently, we found that miR-143#12 inhibited the activation of K-Ras by silencing Sos1, a Ras-specific GEF, thus establishing a "positive circuit" for enhancement of K-Ras mRNA expression by K-Ras effector signaling, as disclosed by using this potent miR-143#12. Our data indicated that the potent silencing of plural genes by RNase-resistant miR-143#12 is a reasonable strategy against mutant K-Ras networks in K-Ras-driven cancers.
| MATERIALS AND METHODS

| Cell culture and cell viability
DLD-1, SW48, HT29 and SW480 cells were purchased from the Japanese Collection Research Bioresources Cell Bank (Osaka, Japan).
Cell line authentication was done by short tandem repeat (STR) analysis, which was performed by using primers of TH01, TPOX, vWA, amelogenin, CSF1PO, D16S539, D7S820, D13S317, D5S818 and D21S11 (GenePrint 10 System; Promega, Madison WI, USA). In addition, sequencing of the K-Ras mutation in the hot regions was performed. These cell lines were used within 6 months of purchase and tested for mycoplasma contamination by using a MycoAlert Mycoplasma Detection Kit (LT07-118, Lonza, Rockland, ME, USA ) and siRNA for Sos1 (siR-Sos1: 2, 5 nmol L À1 ) was used for the transfection of the cells, which was achieved by using Lipofectamine RNAiMAX. . b-actin was used as an internal control. E, Expression levels of K-Ras mRNA as relative ratios with respect to the GAPDH expression level. The expression level of mRNA was calculated using the DDCt method. F, DLD-1 cells were transfected with control-miR, Am, #1 or #12 at 10 nmol L À1 for 72 h. The level of K-Ras-GTP was estimated by performing western blot analysis at 72 h after the transfection. The levels of GTP-bound K-Ras were quantified by densitometry scanning and normalized to the total levels of K-Ras. 
| Syn-miR-143 silenced Sos1 by RNAi
In Figure 1F , we show that the ectopic expression of syn-miR-143
decreased the level of K-Ras-GTP. Among the Ras-GEF families identified in mammals, the Sos proteins are the most widely expressed and functionally relevant for Ras activation by upstream cellular signals. 34, 35 According to in silico prediction tools in Tar ) for 48 h. The cell viability was estimated at 48 h after the transfection. The cell viability control (0; control-miR alone) is indicated as 100%. G, Western blot analysis was performed to determine the levels of Sos1, Ras, p-AKT, AKT, p-ERK1/2 and ERK1/2 proteins. b-actin was used as an internal control. H, DLD-1 cells were transfected with siR-Sos1 (2, 5 nmol L À1 ) for 48 h. The expression level of K-Ras mRNA as relative ratios with respect to the GAPDH expression level was evaluated by RT-qPCR. The expression level of control (0; control-miR alone) is indicated as "1." I, DLD-1 cells were transfected with control or siR-Sos1 for 48 h. The level of K-Ras-GTP was estimated by performing western blot analysis at 48 h after the transfection. The levels of GTP-bound K-Ras were quantified by densitometry scanning and normalized to the total levels of K-Ras. *P < .05 vs control (Student's t test) in the figures altogether indicated that syn-miR-143 targeted Sos1. Next, we examined the effect of Sos1 on growth and the expression of total Ras. The cell viability at 48 hours was significantly suppressed by silencing of Sos1 using siRNA for Sos1 (siR-Sos1; Figure 3F ). However, the effector signaling of K-Ras (ie PI3K/AKT and MAPK/ ERK1/2) remained unchanged at 48 hours after the transfection ( Figure 3G ). The expression level of Ras was slightly decreased at both protein and mRNA levels ( Figure 3G,H) . The K-Ras-GTP levels were markedly suppressed at 10 nmol L À1 ( Figure 3I ). These results indicated that the knockdown of Sos1 induced growth suppression, but barely caused a decrease in the expression level of K-Ras.
Therefore, the knockdown of Sos1 did not affect the K-Ras effector signaling directly ( Figure 3G ). It is possible that the EGF/EGFR/ K-Ras signaling may have functioned for residual K-Ras activation.
These results altogether indicated that syn-miR-143 decreased the expression level of K-Ras through inactivating both PI3K/AKT and MAPK/ERK1/2 signal pathways, and also by silencing Sos1 (Figure 4 ).
| Growth inhibition by combined treatment with syn-miR-143 and cetuximab
The effectiveness of cetuximab is now limited to patients with KRas wild-type tumors. 16 Above we showed that the ectopic expression of syn-miR-143 significantly decreased the levels of KRas mRNA and K-Ras-GTP through perturbation of the positive circuit and activation of K-Ras-GDP. However, the upstream signaling via EGFR was still functional even though the miR-143 downregulated EGFR somewhat ( Figure 4 and Figure S4 ). Therefore, we evaluated whether syn-miR-143 could restore the effect of EGFR inhibitors such as anti-EGFR antibody (cetuximab) or the low-molecular-weight lapatinib on the DLD-1 cell line. First, we Figure 5C ). In addition, we evaluated the restoration effect of cetuximab by using siR-KRas alone in the same experiment. The combined treatment with siR-KRas and cetuximab showed approximately 40% growth suppression; however, the synergistic effect was not significant ( Figure 5D ). The levels of p-AKT and p-ERK1/2
were clearly decreased by the combination treatment with siRKRas and cetuximab ( Figure 5E ). In contrast to syn-miR-143, the expression levels of AKT and ERK1/2 were unchanged, and also the downregulated K-Ras by siR-KRas alone was recovered even in combination treatment with cetuximab. It is likely that the increased expression levels of ERK1/2 and AKT may have stimulated the K-Ras positive circuit, which would have been resistant to the EGFR inhibitor. Some compensatory pathways leading to a positive circuit could be at work when K-Ras alone is silenced.
Next, we evaluated the effect of syn-miR-143 on lapatinib, the first dual inhibitor of EGFR. The IC 50 value of lapatinib is indicated in Figure 5F . The combination treatment with syn-miR-143 The cell viability of the control (Control; control-miR and PBS) is indicated as 100%. E, Western blot analysis was performed to determine the levels of ERK5, Ras, p-ERK1/2, ERK1/2, p-AKT, AKT and PARP-1 proteins. b-actin was used as an internal control. F, DLD-1 cells were treated with lapatinib for 24 h. The cell viability was estimated at 24 h after the treatment. The cell viability was estimated at 72 h after the transfection. The cell viability of the control (0; PBS alone) is indicated as 100%. G, DLD-1 cells were transfected with control-miR, #1 or #12 for 48 h and then treated with lapatinib for 24 h. The cell viability was estimated at 72 h after the transfection. The cell viability of the control (Control; control-miR and PBS) is indicated as 100%. *P < .05 vs control (Student's t test) in the figures were administrated systemically every 72 hours (750 lg/kg/administration) 4 times to nude mice that had been subcutaneously inoculated with DLD-1 (K-Ras G13D ) cells. At day 10 (before the 2nd administration), obvious suppression of tumor growth was already observed in the group injected with syn-miR-143 compared with the growth in the control miR-injected group ( Figure 6A ). We evaluated the benefit of high-dose (1125 lg/kg) #12 (#12 9 1.5 times).
As a result, the group injected with it showed a more potent tumor suppressive effect than the low-dose group; and this effect was prolonged up to the final day 19 ( Figure 6A ). The loss of body weight was not observed in any of the groups ( Figure 6B ). The expression levels of Ras and K-Ras effector signaling molecules were extremely decreased in the samples from syn-miR-143-treated tumors, estimated as protein expression by western blot analysis ( Figure 6C ).
Next, we re-evaluated whether syn-miR-143 restored the effect of anti-EGFR antibody (cetuximab) as seen in the in vitro study.
The concentration of cetuximab was fixed at 10 mg/kg, which was equal to that used clinically. 36 Importantly, the combination treat- will be useful for such clarification. Furthermore, a well-modified drug delivery system will be required to distribute miR-143#12 into tumors as an RNA medicine against Ras-driven cancers.
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